Exclusion of close linkage between the synaptic vesicular monoamine transporter locus and schizophrenia spectrum disorders

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 60, Issue 6, 1995, Pages 563-565

  Persico, A M ^a   Zhe Wu Wang, ^a   Black, D W ^a   Andreasen, N C ^a   Uhl, G R ^a   Crowe, R R ^a  

^a NIDA Addiction Research Center   (United States)

Author keywords

dopamine; epinephrine; histamine; norepinephrine; serotonin

Indexed keywords

ADRENALIN; DOPAMINE; HISTAMINE; NORADRENALIN; SEROTONIN;

ARTICLE; DOPAMINE UPTAKE; DRUG UPTAKE; GENE LOCUS; GENETIC LINKAGE; HUMAN; INTRACELLULAR TRANSPORT; PEDIGREE ANALYSIS; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONIN UPTAKE; SYNAPSE VESICLE;

EID: 0029620626     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.1320600616     Document Type: Article

References (16)

1. Creese I, Burt DL, Snyder SH (1976): Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481–483.
2. Edwards RH (1992): The transport of neurotransmitter into synaptic vesicles. Curr Op Neurobiol 2: 586–594.
3. Farmer AE, McGuffin P, Gottesman II (1987): Twin concordance for DSM‐III schizophrenia—Scrutinizing the validity of the definition. Arch Gen Psychiatry 44: 634–641.
4. Gonzalez AM, Walther D, Pazos A, Uhl GR (1994): Synaptic vesicular monoamine transporter expression: Distribution and pharmacologic profile. Mol Brain Res 22: 219–226.
5. Iversen LL (1973): Catecholamine uptake processes. Br Med Bull 29: 130–135.
6. Kendler KS, McGuire M, Gruenberg AM, O'Hare A, Spellman M, Walsh D (1993): The Roscommon Family Study: Methods, diagnosis of probands and risk of schizophrenia in relatives. Arch Gen Psychiatry 50: 527–540.
7. Liu Y, Peter D, Roghani A, Schuldiner SS, Prive GG, Eisenberg D, Brecha N, Edwards RH (1992): A cDNA that suppresses MPP + toxicity encodes a vesicular amine transporter. Cell 70: 539–551.
8. Losonczy MF, Davidson M, Davis KL (1987): The dopamine hypothesis of schizophrenia. In Meltzer HY (ed): “ Psychopharmacology: The Third Generation of Progress.” New York: Raven Press, pp. 715–726.
9. Persico AM, Wang ZW, Black DW, Andreasen NC, Uhl GR, Crowe RR (1995): Dopamine transporter gene: Exclusion of close linkage with schizophrenia spectrum disorders. Am J Psychiatry 152: 134–136.
10. Ploughman LM, Boehnke M (1989): Estimating the power of a proposed linkage study for a complex genetic trait. Am J Hum Genet 44: 543–551.
11. Risch N, Claus E, Giuffra L (1989): Linkage and mode of inheritance in complex traits. In Elston RC, Spence MA, Hodge SE, MacCluer JW (eds): “ Multipoint Mapping and Linkage Based Upon Affected Pedigree Members: Genetic Analysis Workshop 6.” New York: Alan R. Liss, Inc, pp. 183–188.
12. Surratt CK, Persico AM, Yang XD, Edgar SR, Bird GS, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR (1993): A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies Taq I RFLPs. FEBS Lett 318: 325–330.
13. Van Kammen DP, Gelernter J (1987a): Biochemical instability in schizophrenia I: The norepinephrine system. In Meltzer HY (ed): “ Psychopharmacology: The Third Generation of Progress.” New York: Raven Press, pp. 745–752.
14. Van Kammen DP, Gelernter J (1987b): Biochemical instability in schizophrenia II: The serotonin and γ‐aminobutyric acid systems. In Meltzer HY (ed): “ Psychopharmacology: The Third Generation of Progress.” New York: Raven Press, pp. 753–758.
15. Wang ZW, Black D, Andreasen NC, Crowe RR (1993a): Pseudoautosomal locus for schizophrenia excluded in 12 pedigrees. Arch Gen Psychiatry 50: 199–204.
16. Wang ZW, Black D, Andreasen NC, Crowe RR (1993b): A linkage study of chromosome 11q in schizophrenia. Arch Gen Psychiatry 50: 212–216.